New drug trial aims to reduce bleeding in blood disorder patients
NCT ID NCT06754852
Summary
This early-stage study is testing a new drug called HMB-002 for adults with Von Willebrand Disease, a genetic bleeding disorder. Researchers want to see if the drug is safe, how it works in the body, and if it can reduce how often people experience bleeding episodes. The study will test different doses and look at how well the drug helps control bleeding over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fiona Stanley Hospital
NOT_YET_RECRUITINGMurdoch, Perth, WA 6150, Australia
-
Richmond Pharmacology
RECRUITINGLondon, SE1 1YR, United Kingdom
-
Royal Prince Alfred Hospital
RECRUITINGCamperdown, Sydney, NSW 2050, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.